Literature DB >> 29376891

Hypothalamic loss of Snord116 and Prader-Willi syndrome hyperphagia: the buck stops here?

Juan A Rodriguez1, Jeffrey M Zigman1,2,3.   

Abstract

Hyperphagia and obesity are the best-known manifestations of Prader-Willi syndrome (PWS) and are responsible for most of the overall morbidity and mortality associated with the disease. Yet these PWS symptoms remain poorly understood and without effective pharmacologic therapies. Mouse models attempting to recapitulate both the genetic alterations and marked hyperphagia plus obesity of PWS have been enigmatic, leading to skepticism about the use of mouse models to investigate PWS. In this issue of the JCI, Polex-Wolf and colleagues challenge the skeptics by successfully inducing hyperphagia following bilateral mediobasal hypothalamic deletion of the Snord116 gene from adult mice. Obesity also resulted, although only in a subset of mice. While this approach represents an exciting advance, highlighting a pathologic effect of loss of mediobasal hypothalamic Snord116 expression on the development of PWS's hallmark symptoms, the variability in the body-weight and body composition responses to this site-selective gene deletion raises several questions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29376891      PMCID: PMC5824859          DOI: 10.1172/JCI99725

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  The musculoskeletal manifestations of Prader-Willi syndrome.

Authors:  Jong Sup Shim; Sang Hak Lee; Sung Wook Seo; Kyung Hyo Koo; Dong Kyu Jin
Journal:  J Pediatr Orthop       Date:  2010-06       Impact factor: 2.324

2.  Approach to the child with prader-willi syndrome.

Authors:  Jennifer L Miller
Journal:  J Clin Endocrinol Metab       Date:  2012-11       Impact factor: 5.958

3.  Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome.

Authors:  Lisa C Burnett; Charles A LeDuc; Carlos R Sulsona; Daniel Paull; Richard Rausch; Sanaa Eddiry; Jayne F Martin Carli; Michael V Morabito; Alicja A Skowronski; Gabriela Hubner; Matthew Zimmer; Liheng Wang; Robert Day; Brynn Levy; Ilene Fennoy; Beatrice Dubern; Christine Poitou; Karine Clement; Merlin G Butler; Michael Rosenbaum; Jean Pierre Salles; Maithe Tauber; Daniel J Driscoll; Dieter Egli; Rudolph L Leibel
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

4.  Recommendations for the investigation of animal models of Prader-Willi syndrome.

Authors:  James L Resnick; Robert D Nicholls; Rachel Wevrick
Journal:  Mamm Genome       Date:  2013-04-23       Impact factor: 2.957

Review 5.  Mouse models of Prader-Willi Syndrome: a systematic review.

Authors:  Sandrina Bervini; Herbert Herzog
Journal:  Front Neuroendocrinol       Date:  2013-02-04       Impact factor: 8.606

6.  Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male Snord116 deletion mouse model for Prader-Willi syndrome.

Authors:  Dahe Lin; Qi Wang; Haiying Ran; Kai Liu; Yao Wang; Juanjuan Wang; Yazhen Liu; Ruichuan Chen; Yuxiang Sun; Runzhong Liu; Feng Ding
Journal:  Endocrinology       Date:  2014-04-15       Impact factor: 4.736

7.  Prader-Willi syndrome: consensus diagnostic criteria.

Authors:  V A Holm; S B Cassidy; M G Butler; J M Hanchett; L R Greenswag; B Y Whitman; F Greenberg
Journal:  Pediatrics       Date:  1993-02       Impact factor: 7.124

8.  Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.

Authors:  Roderick F A de Lind van Wijngaarden; Luuk W L de Klerk; Dederieke A M Festen; Hugo J Duivenvoorden; Barto J Otten; Anita C S Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2009-01-21       Impact factor: 5.958

9.  Functional role of suppressor of cytokine signaling 3 upregulation in hypothalamic leptin resistance and long-term energy homeostasis.

Authors:  Alison S Reed; Elizabeth K Unger; Louise E Olofsson; Merisa L Piper; Martin G Myers; Allison W Xu
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

Review 10.  Molecular and anatomical determinants of central leptin resistance.

Authors:  Heike Münzberg; Martin G Myers
Journal:  Nat Neurosci       Date:  2005-05       Impact factor: 24.884

View more
  5 in total

Review 1.  Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor.

Authors:  Gianfabio Giorgioni; Fabio Del Bello; Wilma Quaglia; Luca Botticelli; Carlo Cifani; E Micioni Di Bonaventura; M V Micioni Di Bonaventura; Alessandro Piergentili
Journal:  J Med Chem       Date:  2022-02-14       Impact factor: 7.446

2.  Ghrelin Receptor Agonist Rescues Excess Neonatal Mortality in a Prader-Willi Syndrome Mouse Model.

Authors:  Juan A Rodriguez; Emily C Bruggeman; Bharath K Mani; Sherri Osborne-Lawrence; Caleb C Lord; Henry F Roseman; Hannah L Viroslav; Prasanna Vijayaraghavan; Nathan P Metzger; Deepali Gupta; Kripa Shankar; Claudio Pietra; Chen Liu; Jeffrey M Zigman
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

Review 3.  What can we learn from PWS and SNORD116 genes about the pathophysiology of addictive disorders?

Authors:  Juliette Salles; Emmanuelle Lacassagne; Sanaa Eddiry; Nicolas Franchitto; Jean-Pierre Salles; Maithé Tauber
Journal:  Mol Psychiatry       Date:  2020-10-20       Impact factor: 15.992

4.  Functional diversity of small nucleolar RNAs.

Authors:  Tomaž Bratkovič; Janja Božič; Boris Rogelj
Journal:  Nucleic Acids Res       Date:  2020-02-28       Impact factor: 16.971

Review 5.  "A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes".

Authors:  Deepali Gupta; Sean B Ogden; Kripa Shankar; Salil Varshney; Jeffrey M Zigman
Journal:  Mol Metab       Date:  2020-11-25       Impact factor: 7.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.